Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.
Breast. 2018 Feb 20;39:14-18
Authors: Maurer C, Ferreira AR, Martel S, Lambertini M, Pondé N, Aftimos P, de Azambuja E, Piccart M
Abstract
This is a single center retrospective analysis of patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing after ≥ 4 treatment lines treated with palbociclib in combination with endocrine therapy within a compassionate use program. Thirty-four patients were included between 10/2015 and 02/2017, the majority (82.4%) being previously treated with mTOR inhibitors. Disease control rate was 52.9% and 24.4% at week 12 and 24. Overall progression-free survival was 3.1 months with no difference between mTOR inhibitor-pretreated (3.5 months) and -naïve patients (2.7 months; hazard ratio, 0.83). Toxicity profile in this population was comparable to that seen in previous trials.
PMID: 29474991 [PubMed - as supplied by publisher]

Source: Breast - February 20, 2018 Category: Cancer & Oncology Authors: Maurer C, Ferreira AR, Martel S, Lambertini M, Pondé N, Aftimos P, de Azambuja E, Piccart M Tags: Breast Source Type: research